DGXQuest Diagnostics

$231.15+28% 1Y

$231.15

$171.9552 weeks$247.58

DGX in its own filings

Nothing in DGX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

511

Events found in the filings · across 2,397 filings · the record starts in 1997

Hard flags: none
Hard flags
Most recent filing: Oct 6, 2026
Most recent filing · Form 8-K
Record starts: Mar 19, 1997
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 20, 2026
Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares: 2007-01-22
Material impairment2 occurrences: 2006-07-11
SEC comment-letter activity33 occurrences: 2016-04-29

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 6, 2026On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027.Director or officer change · Form 8-K
Jul 23, 2026Quest Diagnostics Reports Second Quarter 2026 Financial Results;.Earnings release · press release
May 8, 2026On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”)Material agreement entered · Form 8-K
May 1, 2026On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement.Other event · Form 8-K
Apr 21, 2026Quest Diagnostics Reports First Quarter 2026 Financial Results;.Earnings release · press release
Mar 12, 2026On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director.Director or officer change · Form 8-K
Feb 10, 2026On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per …Earnings release · Form 8-K
Jan 12, 2026Driving Sustainable Growth, Delivering Long-term Value.Earnings release · press release